1-(3-azetidin-1-yl-propyl)-1H-pyrazol-3-ylamine | 581082-05-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 亚胺内酰胺
• 英文名称: 1-(3-azetidin-1-yl-propyl)-1H-pyrazol-3-ylamine
• 英文别名: 1-[3-(azetidin-1-yl)propyl]pyrazol-3-amine
• CAS: 581082-05-5
• 化学式: C₉H₁₆N₄
• 分子量: 180.253
• InChiKey: STVWQIMGVDESEN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  47.1
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3,4,5,6-tetrahydro-2,3,10-triaza-benzo[e]azulene-1-carboxylic acid 、 1-(3-azetidin-1-yl-propyl)-1H-pyrazol-3-ylamine 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 在 4-二甲氨基吡啶 碳酸氢钠 、 水 、 Sodium sulfate-III 、 silica gel 、 甲醇 、 二氯甲烷 作用下， 以 1,2-二氯乙烷 、 二氯甲烷 为溶剂， 反应 16.0h， 以yields 12 mg of 3,4,5,6-tetrahydro-2,3,10-triaza-benzo[e]azulene-1-carboxylic acid [1-(3-azetidin-1-yl-propyl)-1H-pyrazol-3-yl]-amide as a colorless foam的产率得到3,4,5,6-tetrahydro-2,3,10-triaza-benzo[e]azulene-1-carboxylic acid [1-(3-azetidin-1-yl-propyl)-1H-pyrazol-3-yl]-amide
  参考文献：
  名称：

  Substituted fused pyrazolecarboxylic acid arylamides and related compounds

  摘要：

  本发明揭示了杂环化合物，如3,4,5,6-四氢-2,3,10-三氮杂苯[e]吲哚-1-羧酸芳基酰胺，5,7-二氢-6H-吡唑并[3,4-h]喹啉-9-羧酸芳基酰胺，5,7-二氢-6H-吡唑并[3,4-h]喹唑啉-9-羧酸芳基酰胺，2,4,5,6-四氢-1,2,6,7-四氮杂萘-8-羧酸芳基酰胺及相关化合物。这些化合物对GABAA脑受体具有高度选择性的激动剂、拮抗剂或反向激动剂，或是GABAA脑受体激动剂、拮抗剂或反向激动剂的前药，因此在治疗焦虑、抑郁、睡眠和癫痫障碍、苯二氮平药物过量、阿尔茨海默病和增强记忆方面非常有用。此外，还提供了包装的制药组合物。还提供了用于合成吡唑酸芳基酰胺的中间体。本发明的化合物还可用作组织样品中GABAA受体的定位探针。

  公开号：

  US06852730B2

文献信息

• SUBSTITUTED FUSED PYRAZOLECARBOXYLIC ACID ARYLAMIDES AND RELATED COMPOUNDS
  申请人：Neurogen Corporation

  公开号：EP1472252A1

  公开（公告）日：2004-11-03
• US6852730B2
  申请人：——

  公开号：US6852730B2

  公开（公告）日：2005-02-08
• US6949562B2
  申请人：——

  公开号：US6949562B2

  公开（公告）日：2005-09-27
• [EN] SUBSTITUTED FUSED PYRAZOLECARBOXYLIC ACID ARYLAMIDES AND RELATED COMPOUNDS<br/>[FR] ARYLAMIDES D'ACIDE PYRAZOLECARBOXYLIQUE SUBSTITUES, FUSIONNES, ET COMPOSES ASSOCIES
  申请人：NEUROGEN CORP

  公开号：WO2003066634A1

  公开（公告）日：2003-08-14

  Heterocyclic compounds such as 3,4,5,6-tetrahydro-2,3,10-triaza-benzo[e]azulene-1-carboxylic acid arylamides, 5,7-Dihydro-6H-pyrazolo[3,4-h]quinoline-9-carboxylic acid arylamides, 5,7-Dihydro-6H-pyrazolo[3,4-h]quinazoline-9-carboxylic acid arylamides, 2,4,5,6-Tetrahydro-1,2,6,7-tetraaza-as-indacene-8-carboxylic acid arylamides and related compounds are disclosed. These compounds are highly selective agonists, antagonists or inverse agonists for GABAA brain receptors or prodrugs of agonists, antagonists or inverse agonists for GABAA brain receptors and are therefore useful in the treatment of anxiety, depression, sleep and seizure disorders, overdose with benzodiazepine drugs, Alzheimer's dementia, and for enhancement of memory. Pharmaceutical compositions, including packaged pharmaceutical compositions, are further provided. Intermediates useful for the synthesis of pyrazolecarboxylic acid arylamides are also provided. Compounds of the invention are also useful as probes for the localization of GABAA receptors in tissue samples.
• Substituted fused pyrazolecarboxylic acid arylamides and related compounds
  申请人：Neurogen Corporation, A Corporation of the State of Delaware

  公开号：US20030216379A1

  公开（公告）日：2003-11-20

  Heterocyclic compounds such as 3,4,5,6-tetrahydro-2,3,10-triaza-benzo[e]azulene-1-carboxylic acid arylamides, 5,7-Dihydro-6H-pyrazolo[3,4-h]quinoline-9-carboxylic acid arylamides, 5,7-Dihydro-6H-pyrazolo[3,4-h]quinazoline-9-carboxylic acid arylamides, 2,4,5,6-Tetrahydro-1,2,6,7-tetraaza-as-indacene-8-carboxylic acid arylamides and related compounds are disclosed. These compounds are highly selective agonists, antagonists or inverse agonists for GABA A brain receptors or prodrugs of agonists, antagonists or inverse agonists for GABA A brain receptors and are therefore useful in the treatment of anxiety, depression, sleep and seizure disorders, overdose with benzodiazepine drugs, Alzheimer's dementia, and for enhancement of memory. Pharmaceutical compositions, including packaged pharmaceutical compositions, are further provided. Intermediates useful for the synthesis of pyrazolecarboxylic acid arylamides are also provided. Compounds of the invention are also useful as probes for the localization of GABA A receptors in tissue samples.

  本发明涉及杂环化合物，例如3,4,5,6-四氢-2,3,10-三氮杂苯[ e ]蓝-1-羧酸芳基酰胺，5,7-二氢-6H-吡唑并[3,4-h]喹啉-9-羧酸芳基酰胺，5,7-二氢-6H-吡唑并[3,4-h]喹唑啉-9-羧酸芳基酰胺，2,4,5,6-四氢-1,2,6,7-四氮杂萘-8-羧酸芳基酰胺及相关化合物。这些化合物是高选择性的GABAA脑受体激动剂、拮抗剂或反向激动剂，或者是GABAA脑受体激动剂、拮抗剂或反向激动剂的前药，因此对于焦虑、抑郁、睡眠和癫痫障碍、苯二氮平类药物过量、阿尔茨海默病和增强记忆等方面的治疗是有用的。此外，还提供了包括包装的制药组合物在内的制药组合物。还提供了用于合成吡唑酸芳基酰胺的中间体。本发明的化合物还可用作组织样品中GABAA受体的定位探针。